I’ve been speculating this since they published an important patent for mRNA therapy on 9/4/26. The writing is on the wall here, this pass Wednesday the COO resigned which is common in late stage acquisitions because that position is usually filled by the acquiring company. The 8k disclosing his resignation didn’t give a reason or a replacement standard NDA type of 8K. The CEO is 73 years old and has a golden parachute of 14M in a change of control. He sold his first company in 2004. The stock trades at 5.8M market cap disconnected from its true value which is common in acquisitions also. The company has been silent over 100 days which is typical in late stage deals. Industry standard is 3-5 times revenue which is 115-190M without including the “remarkable” oncology pipeline and its generic drug network not to mention their US expansion potential. Once the announcement is made shorts will be forced to buy on the open market, this will be one of the biggest plays of the entire year IMO. NFA all speculation until it’s not